Generic Name: pazopanib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Votrient is a multikinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma) and previously treated soft tissue sarcoma.
Votrient is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, PDGFR and KIT, that play a role in cancer cell growth and development of blood vessels.
Clinical trials showed that Votrient delayed disease progression in previously treated or untreated people with advanced renal cell carcinoma and patients with soft tissue sarcoma previously treated with chemotherapy. Votrient was first approved in 2009.
Votrient is given as a once-daily tablet.
Common side effects include fatigue diarrhea, high blood pressure, hair depigmentation, nausea, loss of appetite, vomiting, altered taste sensation, and muscle pain. Potential serious side effects may include liver and heart problems, blood clots, severe bleeding, severe hypertension, gastrointestinal perforation, hypothyroidism and infections. Votrient can cause fetal harm if used during pregnancy.
For More Info: https://www.us.votrient.com/
Patient Assistance Program Info: https://www.hcp.novartis.com/products/votrient/advanced-renal-cell-carcinoma/access/
Last Reviewed: March 24, 2019